Objective To study the efficacy of semiglutide combined with dapagliflozin and metformin in patients with obese type 2 diabetes mellitus(T2DM)and non-alcoholic fatty liver disease(NAFLD).Methods A total of 80 obese patients with T2DM combined with NAFLD were selected from the department of endocrinology of Shouxian People's Hospital from June 2021 to June 2023.They were divided into control group and observation group according to ran-dom number table method,40 cases each.The control group received metformin with dagagliflozin,and the observa-tion group was treated with semegallutide on the basis of the control group.Comparing the efficacy and the incidence of adverse drug reactions after 12 weeks of treatment.Results The homa-ir insulin resistance index,blood glucose in-dex,blood lipid index and liver function index were significantly lower than that of the control group,and the differ-ences were statistically significant(all P<0.05).The body mass index in the observation group was(28.19±0.92)kg/m2,which was lower than(30.12±1.47)kg/m2 in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was not significant(P>0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of obese T2DM patients with NAFLD,compared with the treatment of dapagliflozin and metformin alone,the combination of semaglu-tide has better effects in reducing blood glucose,blood lipids,liver enzymes,and improving islet function,and there is no significant increase in adverse reactions.
维普
万方数据
